Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis

Harrison, Sean; Lennon, Rosie; Holly, Jeff; Higgins, Julian P. T.; Gardner, Mike; Perks, Claire; Gaunt, Tom; Tan, Vanessa; Borwick, Cath; Emmet, Pauline; Jeffreys, Mona; Northstone, Kate; Rinaldi, Sabina; Thomas, Stephen; Turner, Suzanne D.; Pease, Anna; Vilenchick, Vicky; Martin, Richard M.; Lewis, Sarah J.

doi:10.1007/s10552-017-0883-1

Table 6 Characteristics of IGF–Pca animal studies ordered by study type (transgenic or xenograft models) and year of publication

From: Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis

See More Author (year)	Model	Experimental	Control	n (exp:control)	Outcome	Follow-up	Effects estimate	Overall risk of bias
Animal studies
Silha (2006)	Transgenic mice, where experimental over-express IGFBP3	LPB Tag /PGKBP-3; LPB Tag/CMVBP-3	LPB Tag/WT	231	Tumor weight	21 weeks	p < 0.001 tumors smaller in experimental	Unclear
Sutherland (2008)	Transgenic IGFR knockout mice	IGFR KO (Cre/loxP) IGFR titrated (Cre/wt)	IGF-IR intact (loxP/loxP; loxP/WT)	66	Tumor weight	12 weeks	IGFR intact vs IGFR titrated p = 0.02	Unclear
Anzo (2008)	Transgenic TRAMP mice, targeted deletion of Igf1	LID-TRAMP mice, where LID have deleted Igf1 gene and low levels of IGF-I	L/L-TRAMP mice	45 (25;20)	Tumor progression (Lymph node metastasis)	36 weeks	p = 0.93 (% mice with metastasis)	Unclear
Mehta (2011)	Transgenic (knockout) mice deficient in IGFBP3	IGFBP-3KO:Myc	WT:Myc	NS	Tumor progression; lung metastasis	80 weeks	p < 0.05 (% mice with metastasis), higher for experimental	Unclear
Goya (2004)	Xenograft of human cell line and human adult bone in NOD/SCID mice	Antibody against IGF-I and IGF-II (KMI468)	Control antibody (KMI762)	NS	Bone tumor area	4 weeks	p < 0.001 tumors smaller in experimental	Unclear
Wu (2005)	Human cell line-derived xenograft in nude mice	Antibody A12- anti IGF-IR	Saline solution	NS	Tumor volume	5 weeks	p < 0.05 tumors smaller in experimental	Unclear
Ingermann (2010)	Human cell line-derived xenograft in nude mice	IGFBP3R binds to IGFBP3	PBS solution	NS	Tumor volume	16 days	Control: 302 ± 54.5 mm³ Exp.193 ± 28.6 mm³	Unclear
Kimura (2010)	Xenograft of human cell line and human adult bone in NOD/SCID mice	Antibody against IGF2 (M610)	Control antibody (M102.4)	24 (16; 8)	Bone tumor area	4 weeks	Control: 2.2 ± 0.9 mm² Exp.: 0.8 ± 1.2 mm² p = 0.01	Unclear
Supporting evidence
DiGiovanni (2000)	Transgenic mice BK5.IGF- mice, over expression of IGF-1	BK5.IGF-1 transgenic mice	Non-transgenic mice	NS	Hallmarks of cancer	Various	Supporting evidence only	Unclear
Fu (2008)	Transgenic	C57/B6 mice	N/A	NS	LOI in IGF-2	NS	Supporting evidence only	Unclear

Back to article page